These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29281036)

  • 1. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).
    Holland TL; O'Riordan W; McManus A; Shin E; Borghei A; File TM; Wilcox MH; Torres A; Dryden M; Lodise T; Oguri T; Corey GR; McLeroth P; Shukla R; Huang DB
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
    Noviello S; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Scaramucci A; Torres A; Huang DB
    J Med Microbiol; 2020 Apr; 69(4):625-630. PubMed ID: 32195649
    [No Abstract]   [Full Text] [Related]  

  • 5. A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies.
    Huang DB; Noviello S; Balser B; Scaramucci A; Corey GR
    Clin Ther; 2019 Jun; 41(6):1090-1096. PubMed ID: 31030995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
    Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
    Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
    Huang DB; File TM; Torres A; Shorr AF; Wilcox MH; Hadvary P; Dryden M; Corey GR
    Clin Ther; 2017 Aug; 39(8):1706-1718. PubMed ID: 28756068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.
    Huang DB; Dryden M
    Future Microbiol; 2018 Jul; 13():957-969. PubMed ID: 29742926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
    Noviello S; Huang DB; Corey GR
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):793-803. PubMed ID: 30317894
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Noviello S; Magnet S; Hawser S; Huang DB
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.
    Noel GJ; Strauss RS; Amsler K; Heep M; Pypstra R; Solomkin JS
    Antimicrob Agents Chemother; 2008 Jan; 52(1):37-44. PubMed ID: 17954698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
    Krievins D; Brandt R; Hawser S; Hadvary P; Islam K
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2834-40. PubMed ID: 19414572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
    Giordano PA; Pogue JM; Cammarata S
    Clin Infect Dis; 2019 Apr; 68(Suppl 3):S223-S232. PubMed ID: 30957167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
    Huang DB; Charrier C; Le Bras C; Hawser S; Noviello S
    J Med Microbiol; 2019 Jun; 68(6):898-902. PubMed ID: 31050628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.
    Lodise TP; Bosso J; Kelly C; Williams PJ; Lane JR; Huang DB
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).
    Overcash JS; Kim C; Keech R; Gumenchuk I; Ninov B; Gonzalez-Rojas Y; Waters M; Simeonov S; Engelhardt M; Saulay M; Ionescu D; Smart JI; Jones ME; Hamed KA
    Clin Infect Dis; 2021 Oct; 73(7):e1507-e1517. PubMed ID: 32897367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose oritavancin in the treatment of acute bacterial skin infections.
    Corey GR; Kabler H; Mehra P; Gupta S; Overcash JS; Porwal A; Giordano P; Lucasti C; Perez A; Good S; Jiang H; Moeck G; O'Riordan W;
    N Engl J Med; 2014 Jun; 370(23):2180-90. PubMed ID: 24897083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linezolid for the treatment of complicated skin and skin structure infections in children.
    Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
    Morgan A; Cofer C; Stevens DL
    Future Microbiol; 2009 Mar; 4(2):131-44. PubMed ID: 19257839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.